Change in the number of shares and votes in Egetis Therapeutics

Summary by AI ^BETAClose X

Egetis Therapeutics AB announced a change in its share structure due to the exercise of employee stock options, resulting in an increase of 3,117,885 ordinary shares and a corresponding decrease in class C shares, bringing the total ordinary shares to 464,947,224 and class C shares to 25,881,381, while the total number of votes rose by 2,806,096.5 to 467,535,362.1, with the share capital remaining unchanged at SEK 25,833,094.110797.

Disclaimer*

Stockholm, Sweden, May 29, 2026. The number of ordinary shares, class C shares and votes in Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) changed during May as a result of the exercise of employee stock options granted under the 2022–2026 employee stock option program.

The total number of shares in the Company remains 490,828,605; however, 3,117,885 class C shares have been converted into ordinary shares. As a result, the number of ordinary shares has increased by 3,117,885, from 461,829,339 to 464,947,224, while the number of class C shares has decreased by 3,117,885, from 28,999,266 to 25,881,381. The total number of votes in the Company has increased by 2,806,096.5, from 464,729,265.6 to 467,535,362.1. The share capital remains unchanged at SEK 25,833,094.110797.

About Egetis Therapeutics

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.

The Company’s lead drug candidate Emcitate® (tiratricol) is developed for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In February 2025 the European Commission approved Emcitate® as the first and only treatment for MCT8 deficiency in EU. Egetis initiated the launch of Emcitate® in Germany on May 1, 2025. Emcitate® (tiratricol) is not approved in the USA.

On March 27, 2026, Egetis announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for Emcitate® (tiratricol) for the treatment of MCT8 deficiency. The application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date, or FDA decision date, of September 28, 2026.

The NDA for Emcitate® (tiratricol) for treatment of MCT8 deficiency is based on clinical data from Triac Trial I, Triac Trial II, ReTRIACt, EMC Cohort Study, EMC Survival Study and the US Expanded Access Program.

Tiratricol holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. Tiratricol has been granted Breakthrough Therapy Designation and Rare Pediatric Disease Designation (RPDD) by the FDA, which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval.

The drug candidate Aladote® (calmangafodipir) is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed. The design of a pivotal Phase IIb/III study (Albatross), with the purpose of applying for market approval in the US and Europe, has been finalized following interactions with the FDA, EMA and MHRA. The development program for Aladote® has been parked. Aladote® has been granted ODD in the US and in the EU.

Egetis Therapeutics is listed on the Nasdaq Stockholm main market (Nasdaq Stockholm: EGTX).
For more information, see www.egetis.com